Replies to post #13650 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

My bet is Sandoz is launching generic copaxone at risk.

If Sandoz didn't take Neupogen to make before the recent court result I see no reason why they'd gamble on Copaxone.

I'm not sure of Momenta's liability (except profits) with a at-risk launch.

[floblu14]

My bet is Sandoz is launching generic copaxone at risk.

I tend to agree -

on April 16 - Leerink Partners analyst Jason Gerberry reiterated an Outperform rating and raised his price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $24 on generic Copaxone approval this afternoon. The product will be sold under the trade name Glatopa, but was approved as an interchangeable ANDA product.

Gerberry commented, "Glatopa launch timing and g-Copaxone pricing remain unknowns and will both be determined by NVS’ (OP) Sandoz. This matters because waiting until 9/1/15 (patent expiry) to launch risks ceding more share of the brand to TEVA's patented 40mg formulation. Copaxone 40mg has converted 65% of the franchise per the last IMS weekly update. Key updates on the CC included (1) MNTA/Sandoz are prepared to launch today & accelerated Federal Circuit ruling on the lone patent would eliminate the only pot'l gating factor; (2) upcoming financing will be used to further MNTA's un-partnered biosimilar pipeline. We are increasing our PT to $24/shr, based on our base case DCF which assumes a 4Q'15 Glatopa launch (exclusive) and partially exclusive generic in 2016."

http://www.streetinsider.com/Analyst+Comments/Momenta+Pharmaceuticals+%28MNTA%29+PT+Lifted+to+$24+at+Leerink+Partners+on+Generic+Copaxone+Approval/10466264.html